Specialized SaaS (Software as a Service) platforms enabling systematic 'mandatory reporting' with just a few clicks are gaining attention. Mandatory reporting refers to the mandatory submission of data and information required by regulatory or operational agencies in various industries. As companies managing critical data in sectors such as medical, bioscience, and carbon management, conforming to regulatory reporting formats through data management and verification is crucial.
However, the problem lies in the fact that the domestic market has not yet properly established such foundations. Many companies struggle due to insufficient capacity for continuous data management required for mandatory reporting, as well as high entry barriers in terms of costs and expertise.
Amidst this, healthcare data platform company JNPMEDI has newly launched the 'Maven Safety' pharmaceutical safety management solution, aiming to provide services that allow small and medium-sized enterprises to easily manage pharmaceutical safety data in accordance with international standards.
Due to the mandatory implementation of the Development Safety Update Report (DSUR) for drug safety management in clinical trials since last year, regulatory requirements related to pharmaceutical safety have been intensifying. However, initial adoption and maintenance costs of safety data management (Safety DB management) software have been high, limiting accessibility for related companies.
Developed by JNPMEDI, Maven Safety is a subscription-based SaaS solution that allows selective adoption of necessary functions based on project objectives and scale, enhancing convenience by enabling usage without separate installation. Particularly designed to facilitate easy data management in compliance with international standard formats, Maven Safety is priced reasonably to meet the essential data management needs of companies that face challenges due to cost burdens.
Maven Safety has enhanced its competitiveness by establishing services that maximize business efficiency, including ▲ optimized regulatory reporting, ▲ collaboration-based safety data management, and ▲ increased productivity in clinical research. It supports systematic data management with features such as data input capabilities aligned with E2B(R3) formats for domestic regulatory reporting, easy file conversion, and streamlined archiving.
Moreover, it offers convenient integration with collaboration-based tools, allowing users to create workspaces and folders within the product, set access permissions separately, and facilitate flexible collaboration with internal and external users, as well as relevant companies and institutions.
Additionally, through audit trail functionalities, Maven Safety prevents manipulation of clinical trial data, ensures integrity, and enables mutual review and exchange of opinions on data using approval and comment features.
Specialized SaaS (Software as a Service) platforms enabling systematic 'mandatory reporting' with just a few clicks are gaining attention. Mandatory reporting refers to the mandatory submission of data and information required by regulatory or operational agencies in various industries. As companies managing critical data in sectors such as medical, bioscience, and carbon management, conforming to regulatory reporting formats through data management and verification is crucial.
However, the problem lies in the fact that the domestic market has not yet properly established such foundations. Many companies struggle due to insufficient capacity for continuous data management required for mandatory reporting, as well as high entry barriers in terms of costs and expertise.
Amidst this, healthcare data platform company JNPMEDI has newly launched the 'Maven Safety' pharmaceutical safety management solution, aiming to provide services that allow small and medium-sized enterprises to easily manage pharmaceutical safety data in accordance with international standards.
Due to the mandatory implementation of the Development Safety Update Report (DSUR) for drug safety management in clinical trials since last year, regulatory requirements related to pharmaceutical safety have been intensifying. However, initial adoption and maintenance costs of safety data management (Safety DB management) software have been high, limiting accessibility for related companies.
Developed by JNPMEDI, Maven Safety is a subscription-based SaaS solution that allows selective adoption of necessary functions based on project objectives and scale, enhancing convenience by enabling usage without separate installation. Particularly designed to facilitate easy data management in compliance with international standard formats, Maven Safety is priced reasonably to meet the essential data management needs of companies that face challenges due to cost burdens.
Maven Safety has enhanced its competitiveness by establishing services that maximize business efficiency, including ▲ optimized regulatory reporting, ▲ collaboration-based safety data management, and ▲ increased productivity in clinical research. It supports systematic data management with features such as data input capabilities aligned with E2B(R3) formats for domestic regulatory reporting, easy file conversion, and streamlined archiving.
Moreover, it offers convenient integration with collaboration-based tools, allowing users to create workspaces and folders within the product, set access permissions separately, and facilitate flexible collaboration with internal and external users, as well as relevant companies and institutions.
Additionally, through audit trail functionalities, Maven Safety prevents manipulation of clinical trial data, ensures integrity, and enables mutual review and exchange of opinions on data using approval and comment features.